Erlend Skaga

  • Post doc; MD, PhD
 

Publications 2024

Skaga E, Trewin-Nybråten CB, Niehusmann P, Johannesen TB, Marienhagen K, Oltedal L, Schipman S, Skjulsvik AJ, Solheim O, Solheim TS, Sundstrøm T, Vik-Mo EO, Petter Brandal, Ingebrigtsen T (2024)
Stable glioma incidence and increased patient survival over the past two decades in Norway: a nationwide registry-based cohort study
Acta Oncol, 63, 83-94
DOI 10.2340/1651-226X.2024.24970, PubMed 38501768

Publications 2023

Brynjulvsen M, Solli E, Walewska M, Zucknick M, Djirackor L, Langmoen IA, Mughal AA, Skaga E, Vik-Mo EO, Sandberg CJ (2023)
Functional and Molecular Heterogeneity in Glioma Stem Cells Derived from Multiregional Sampling
Cancers (Basel), 15 (24)
DOI 10.3390/cancers15245826, PubMed 38136371

Mendoza Mireles EE, Skaga E, Server A, Leske H, Brandal P, Helseth E, Rønning PA, Vik-Mo EO (2023)
The benefit of complete resection of contrast enhancing tumor in glioblastoma patients: A population-based study
Neurooncol Pract, 10 (6), 555-564
DOI 10.1093/nop/npad037, PubMed 38026582

Publications 2022

Skaga E, Kulesskiy E, Potdar S, Panagopoulos I, Micci F, Langmoen IA, Sandberg CJ, Vik-Mo EO (2022)
Functional temozolomide sensitivity testing of patient-specific glioblastoma stem cell cultures is predictive of clinical outcome
Transl Oncol, 26, 101535
DOI 10.1016/j.tranon.2022.101535, PubMed 36115076

Publications 2021

Skaga E, Skretteberg MA, Johannesen TB, Brandal P, Vik-Mo EO, Helseth E, Langmoen IA (2021)
Real-world validity of randomized controlled phase III trials in newly diagnosed glioblastoma: to whom do the results of the trials apply?
Neurooncol Adv, 3 (1), vdab008
DOI 10.1093/noajnl/vdab008, PubMed 33665615

Publications 2020

Kierulf-Vieira KS, Sandberg CJ, Waaler J, Lund K, Skaga E, Saberniak BM, Panagopoulos I, Brandal P, Krauss S, Langmoen IA, Vik-Mo EO (2020)
A Small-Molecule Tankyrase Inhibitor Reduces Glioma Stem Cell Proliferation and Sphere Formation
Cancers (Basel), 12 (6)
DOI 10.3390/cancers12061630, PubMed 32575464

Publications 2019

Hvinden IC, Berg HE, Sachse D, Skaga E, Skottvoll FS, Lundanes E, Sandberg CJ, Vik-Mo EO, Rise F, Wilson SR (2019)
Nuclear Magnetic Resonance Spectroscopy to Identify Metabolite Biomarkers of Nonresponsiveness to Targeted Therapy in Glioblastoma Tumor Stem Cells
J Proteome Res, 18 (5), 2012-2020
DOI 10.1021/acs.jproteome.8b00801, PubMed 30964684

Ottestad W, Rognes IN, Skaga E, Frisvoll C, Haraldsen G, Eken T, Lundbäck P (2019)
HMGB1 concentration measurements in trauma patients: assessment of pre-analytical conditions and sample material
Mol Med, 26 (1), 5
DOI 10.1186/s10020-019-0131-0, PubMed 31892315

Skaga E, Kulesskiy E, Brynjulvsen M, Sandberg CJ, Potdar S, Langmoen IA, Laakso A, Gaál-Paavola E, Perola M, Wennerberg K, Vik-Mo EO (2019)
Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment
Clin Transl Med, 8 (1), 33
DOI 10.1186/s40169-019-0253-6, PubMed 31889236

Skaga E, Kulesskiy E, Fayzullin A, Sandberg CJ, Potdar S, Kyttälä A, Langmoen IA, Laakso A, Gaál-Paavola E, Perola M, Wennerberg K, Vik-Mo EO (2019)
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
BMC Cancer, 19 (1), 628
DOI 10.1186/s12885-019-5861-4, PubMed 31238897

Skaga E, Skaga IØ, Grieg Z, Sandberg CJ, Langmoen IA, Vik-Mo EO (2019)
The efficacy of a coordinated pharmacological blockade in glioblastoma stem cells with nine repurposed drugs using the CUSP9 strategy
J Cancer Res Clin Oncol, 145 (6), 1495-1507
DOI 10.1007/s00432-019-02920-4, PubMed 31028540

Publications 2018

Fayzullin A, Sandberg CJ, Spreadbury M, Saberniak BM, Grieg Z, Skaga E, Langmoen IA, Vik-Mo EO (2018)
Phenotypic and Expressional Heterogeneity in the Invasive Glioma Cells
Transl Oncol, 12 (1), 122-133
DOI 10.1016/j.tranon.2018.09.014, PubMed 30292065

Page visits: 3078